Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer patients pretreated with TDM-1
Published: 18 Dec 2019
Views: 3454
Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA
Dr Ian Krop gives a press conference at the 2019 San Antonio Breast Cancer Symposium about the latest results from the DENSITY-Breast01 study.
Watch our interview with Dr Krop here.
Read more about the study here.
Related Videos
HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-pos...
Dr Rashmi Murthy - MD Anderson Cancer Center, Houston, USA
23 Jan 2020
Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germli...
Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA
19 Dec 2019
Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive b...
Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
19 Dec 2019
Oral paclitaxel with encequidar in metastatic breast cancer
Dr Gerardo Umanzor - Hospital del Valle, San Pedro Sula, Honduras
19 Dec 2019
Combining atezolizumab to neoadjuvant chemotherapy does not improve pathologic c...
Dr Luca Gianni - San Raffaele Hospital, Milan, Italy
18 Dec 2019
Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for the...
Dr Luca Gianni - San Raffaele Hospital, Milan, Italy
18 Dec 2019
APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with op...
Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium
18 Dec 2019
Could trastuzumab deruxtecan become the new standard of care for pretreated HER2...
Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA
18 Dec 2019
Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-p...
Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium
18 Dec 2019
